Molecular chaperones in DNA repair mechanisms: Role in genomic instability and proteostasis in cancer

Hasan, Adria; Rizvi, Suroor Fatima; Parveen, Sana; Mir, Snober S.

doi:10.1016/j.lfs.2022.120852

Cited by 2 publications

(1 citation statement)

References 239 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSPs are classified according to their molecular weights constituting various families—HSPH (HSP110), HSPC (HSP90), HSPA (HSP70), DNAJ (HSP40), small HSP (HSPB), human chaperonin families CCT (TRiC), and HSPD/E ( Table 1 ) [ 14 ]. HSPs play a significant role in tumor cell proteostasis and evasion of apoptosis; they are involved in cancer cell division, DNA repair mechanisms, invasion, and metastasis [ 10 , 12 , 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials

Babi¹,

Menlibayeva²,

Bex³

et al. 2022

Cancers

View full text Add to dashboard Cite

Heat shock proteins (HSPs) are conservative and ubiquitous proteins that are expressed both in prokaryotic and eukaryotic organisms and play an important role in cellular homeostasis, including the regulation of proteostasis, apoptosis, autophagy, maintenance of signal pathways, protection from various stresses (e.g., hypoxia, ionizing radiation, etc.). Therefore, HSPs are highly expressed in tumor cells, including malignant brain tumors, where they also associate with cancer cell invasion, metastasis, and resistance to radiochemotherapy. In the current review, we aimed to assess the diagnostic and prognostic values of HSPs expression in CNS malignancies as well as the novel treatment approaches to modulate the chaperone levels through the application of inhibitors (as monotherapy or in combination with other treatment modalities). Indeed, for several proteins (i.e., HSP10, HSPB1, DNAJC10, HSPA7, HSP90), a direct correlation between the protein level expression and poor overall survival prognosis for patients was demonstrated that provides a possibility to employ them as prognostic markers in neuro-oncology. Although small molecular inhibitors for HSPs, particularly for HSP27, HSP70, and HSP90 families, were studied in various solid and hematological malignancies demonstrating therapeutic potential, still their potential was not yet fully explored in CNS tumors. Some newly synthesized agents (e.g., HSP40/DNAJ inhibitors) have not yet been evaluated in GBM. Nevertheless, reported preclinical studies provide evidence and rationale for the application of HSPs inhibitors for targeting brain tumors.

show abstract